<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a patient who had an <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> aged 22 years, an inherited type I <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo> and a heterozygous genotype of prothrombin gene 20210A </plain></SENT>
<SENT sid="1" pm="."><plain>In view of recent reports of an increased risk for ischemic cerebral <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> in patients with the prothrombin 20210A mutation, we suggest that many of the reported cases of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo> may have had additional prothrombotic disorders such as the prothrombin mutation </plain></SENT>
<SENT sid="2" pm="."><plain>The current data concerning the magnified risk for <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with the prothrombin 20210A mutation suggests the need to study <z:hpo ids='HP_0000001'>all</z:hpo> patients with premature <z:hpo ids='HP_0001297'>stroke</z:hpo> for this mutation and the other risk factors for <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>This would include <z:chebi fb="0" ids="17230">homocysteine</z:chebi>, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> inhibitor, anticardiolipin antibodies, and possibly the natural inhibitors of coagulation </plain></SENT>
<SENT sid="4" pm="."><plain>It is possible that patients with the prothrombin 20210A mutation and ischemic cerebral <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> would benefit from long-term anticoagulation therapy in a similar way to patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>